Your AI-Trained Oncology Knowledge Connection!
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.
Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses the underutilization of bladder preservation in patients with localized bladder cancer.
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.
Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.
Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.
Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.
Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.
Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.
Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.
David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the promise of CAR T-cell therapy in hematologic malignancies.
Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.
Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.
Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.
David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.
Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies.
Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.
Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.
Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.
The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.
Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.
Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).
When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
As the class of agents targeting the PD-1/PD-L1 pathway expands in non–small cell lung cancer, so does the potential population of patients who would be candidates for the groundbreaking immunotherapy.
The perception that cord blood is an inferior source of stem cells is simply not accurate and may result in delays in lifesaving treatment for patients.
The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.
Ten or 15 years ago, a diagnosis of advanced non– small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.
